Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism

Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer

(2016) Gabriel Schmid et al.   BMC CANCER

Urokinase-type Plasminogen Activator (uPA) Promotes Angiogenesis by Attenuating Proline-rich Homeodomain Protein (PRH) Transcription Factor Activity and De-repressing Vascular Endothelial Growth Factor (VEGF) Receptor Expression

(2016) Victoria Stepanova et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating miRNAs

(2016) Xiaofeng Wang et al.   Journal of Hematology & Oncology

Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma

(2016) Virginia Spanò et al.   JOURNAL OF MEDICINAL CHEMISTRY

CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts

(2016) Michelandrea De Cesare et al.   Journal of Translational Medicine

Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth

(2015) Yong Zhao et al.   BIOCHEMICAL PHARMACOLOGY

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin

(2015) Michelandrea De Cesare et al.   Oncotarget

microRNA-34a as a Therapeutic Agent against Human Cancer

(2015) Yoshimasa Saito et al.   Journal of Clinical Medicine

miR-34: from bench to bedside

(2015) Massimiliano Agostini et al.   Oncotarget

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma

(2014) S Zhou et al.   BRITISH JOURNAL OF CANCER

Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells

(2014) Kinga Pénzes et al.   CANCER BIOLOGY & THERAPY

Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy

(2014) Heng Li et al.   Molecular Cancer

MicroRNA-34a: a potential therapeutic target in human cancer

(2014) X J Li et al.   Cell Death & Disease

Mir-34: A New Weapon Against Cancer?

(2014) Gabriella Misso et al.   Molecular Therapy-Nucleic Acids

The Role of Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

(2013) Marcello Deraco et al.   ANNALS OF SURGICAL ONCOLOGY

Synergistic Antitumor Activity of Cetuximab and Namitecan in Human Squamous Cell Carcinoma Models Relies on Cooperative Inhibition of EGFR Expression and Depends on High EGFR Gene Copy Number

(2013) M. De Cesare et al.   CLINICAL CANCER RESEARCH

Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC)

(2013) Dario Baratti et al.   EUROPEAN JOURNAL OF CANCER

Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival

(2013) S Ammoun et al.   ONCOGENE

1p36 Tumor Suppression--A Matter of Dosage?

(2012) K.-O. Henrich et al.   CANCER RESEARCH

MicroRNA and cancer

(2012) Martin D. Jansson et al.   Molecular Oncology

Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors

(2012) Dalia Ercan et al.   Cancer Discovery

miR-34 – a microRNA replacement therapy is headed to the clinic

(2012) Andreas G. Bader   Frontiers in Genetics

Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer

(2011) I. S. Donev et al.   CLINICAL CANCER RESEARCH

Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy

(2011) Marie Brevet et al.   Journal of Thoracic Oncology

AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy

(2011) M V Astle et al.   ONCOGENE

An overview of the c-MET signaling pathway

(2011) Shawna Leslie Organ et al.   Therapeutic Advances in Medical Oncology

Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer

(2010) Dmitri Lodygin et al.   CELL CYCLE

Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma

(2010) Federica Perrone et al.   EUROPEAN JOURNAL OF CANCER

Maspin Regulates Endothelial Cell Adhesion and Migration through an Integrin Signaling Pathway

(2010) Li Qin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma

(2009) Valentina Zuco et al.   BIOCHEMICAL PHARMACOLOGY

ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968

(2009) Valentina Zuco et al.   CANCER LETTERS

MicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes

(2009) Y. Li et al.   CANCER RESEARCH

MicroRNAs: Target Recognition and Regulatory Functions

(2009) David P. Bartel   CELL

The miR-34 family in cancer and apoptosis

(2009) H Hermeking   CELL DEATH AND DIFFERENTIATION

BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4

(2009) Momoko Suzuki et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience

(2009) Tristan D. Yan et al.   JOURNAL OF CLINICAL ONCOLOGY

Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis

(2009) Y Li et al.   ONCOGENE

Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells

(2008) Yasunori Fujita et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells

(2008) Na Li et al.   CANCER LETTERS